Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue        
Product revenue, net $ 15,288 $ 9,415 $ 26,007 $ 21,361
Collaboration revenue 2,400 0 3,200 0
Revenue - related party 155 42 223 1,014
Net revenue 17,843 9,457 29,430 22,375
Operating expenses        
Cost of goods sold - product revenue 7,484 3,124 11,392 6,934
Research and development 22,831 15,703 42,859 30,570
Research and development - licenses acquired 11,003 1,570 11,129 1,820
Selling, general and administrative 19,382 14,456 36,924 29,975
Total operating expenses 60,700 34,853 102,304 69,299
Loss from operations (42,857) (25,396) (72,874) (46,924)
Other income (expense)        
Interest income 146 336 373 963
Interest expense and financing fee (2,760) (3,059) (4,949) (6,184)
Change in fair value of investments 25,005 0 30,918 0
Change in fair value of derivative liability (3,925) (344) (3,925) (386)
Total other income (expense) 18,466 (3,067) 22,417 (5,607)
Net loss (24,391) (28,463) (50,457) (52,531)
Less: net loss attributable to non-controlling interests 20,856 15,149 38,100 26,847
Net loss attributable to common stockholders $ (3,535) $ (13,314) $ (12,357) $ (25,684)
Net loss per common share - basic and diluted $ (0.30) $ (0.42) $ (0.62) $ (0.80)
Net loss per common share attributable to non - controlling interests - basic and diluted (0.26) (0.22) (0.47) (0.41)
Net loss per common share attributable to common stockholders - basic and diluted $ (0.04) $ (0.19) $ (0.15) $ (0.39)
Weighted average common shares outstanding - basic and diluted 80,962,994 68,550,494 80,907,671 66,023,367